Your browser doesn't support javascript.
loading
Combinations of HDAC inhibitor and PPAR agonist induce ferroptosis of leukemic stem cell-like cells in acute myeloid leukemia.
Zhou, Hui; Qin, Dongmei; Xie, Chendi; Zhou, Jie; Jia, Shuman; Zhou, Ziwei; Qiu, Yi; Xu, Bing; Zha, Jie.
Affiliation
  • Zhou H; Xiamen University, China.
  • Qin D; Xiamen University, Xiamen, China.
  • Xie C; Xiamen University, Xiamen, China.
  • Zhou J; Xiamen Nanyang University, Xiamen, China.
  • Jia S; Xiamen University, Xiamen, China.
  • Zhou Z; Fujian Medical University, China.
  • Qiu Y; Pennsylvania State University College of Medicine, United States.
  • Xu B; First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Zha J; First Affiliated Hospital of Xiamen University, Xiamen, China.
Clin Cancer Res ; 2024 Sep 25.
Article in En | MEDLINE | ID: mdl-39321217
ABSTRACT

PURPOSE:

Leukemia stem cells (LSCs) are responsible for leukemia initiation, relapse, and therapeutic resistance. Therefore, the development of novel therapeutic approaches targeting LSCs is urgently needed for patients with AML.

METHODS:

The LSCs-like cell lines (KG-1α and Kasumi-1), CD34+ primary AML cells purified from AML patients (n=23) treated with CS055 and/or chiglitazar and were analyzed for viability, death, and colony formation assay. We performed RNA-seq, Glutamate-Release, Intracellular-GSH, Lipid-ROS, transmission-electron-microscopy, Western-Blotting assay, and confirmed ferroptosis in LSCs-like cells. The luciferase-reporter, co-immunoprecipitation, HDAC3-shRNA/HDAC3/deacetylase-deficient LSCs-like cell lines, His-pull-down, and chromatin-immunoprecipitation assays performed to clarify the molecular mechanism of CS055/chiglitazar in LSCs-like cells. We also established CDX and PDX mouse models to evaluate the therapeutic efficacy of CS055/chiglitazar against-AML in vivo.

RESULTS:

We report that the histone deacetylase inhibitor CS055, in combination with peroxisome proliferator-activated receptor (PPAR) pan-agonist (chiglitazar), synergistically targets leukemia stem-like cells from leukemia cell lines and patient samples, while sparing normal hematopoietic progenitor cells. Mechanistically, chiglitazar enhances the inhibitory effect of CS055 on HDAC3 and induces ferroptosis in LSCs-like cells by down-regulating the expression of ferroptosis suppressor SLC7A11. In fact, the inhibition of HDAC3 increases H3K27AC levels in the promoter region of activating transcription factor 3 (ATF3), a transcriptional repressor of the SLC7A11 gene, and upregulates the expression of ATF3. In contrast, ATF4, a SLC7A11 activator, is suppressed by HDAC3 inhibition.

CONCLUSIONS:

Our findings suggest that treatment with CS055 combined with chiglitazar, will target LSCs by inducing ferroptosis and may confer an effective approach for the treatment of AML.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: China Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: China Country of publication: United States